What is IKT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.27B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IKT?

P/E (TTM) is n/a and 52-week range is $1.33 to $2.61 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IKT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IKT?

The company profile lists revenue (TTM) near $320K, net income (TTM) near $-1.91B, EPS (TTM) near $-0.50 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Inhibikase Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Wilmington, Delaware, US, 157M shares outstanding, ISIN US45719W2052 when available from company profile and filing metadata.

Inhibikase Therapeutics Inc

$IKT

Health Care · Biotechnology

IR Run Scenarios

$1.97

+3.14%

Inhibikase Therapeutics Inc

$IKT

Health Care · Biotechnology

IR Run Scenarios

$1.97

+3.14%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. The company is headquartered in Wilmington, Delaware and currently employs 35 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).

Employees

35

Website

www.inhibikase.com/

IPO

2020-12-23

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US45719W2052

Headquarters

Wilmington, Delaware, US

Shares outstanding

157M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

89.28%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. The company is headquartered in Wilmington, Delaware and currently employs 35 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).

Employees

35

Website

www.inhibikase.com/

IPO

2020-12-23

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)